CD8A and multiple sclerosis: Nevertheless, in the multiple sclerosis patients, both CD4+ and CD8+ T-cells correlated significantly with ALC from treatment initiation to week 96 of observation (r = 0.559−0.880; p < 0.001) (Longbrake et al., 2021).